Clinical Trial Update: Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing once-daily AZD5004 to placebo over 26 weeks in adults with type 2 diabetes assessed efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD5004 (AZD5004)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED